Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02473445 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02473445 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 22 participants.
The verdict
NCT02473445, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study RP103-MITO-001 (NCT02023866).
Interventions
- DRUG Cysteamine Bitartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-05-19 |
| Est. Completion | 2017-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02473445
The ClinicalTrials.gov registry entry for NCT02473445 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cysteamine Bitartrate is the first listed.
NCT02473445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02473445 about?
NCT02473445 is a clinical study titled "A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease". A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study RP103-MITO-001 (NCT02023866).
What is the current status of trial NCT02473445?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-05-19. Estimated completion is 2017-03-06.
What interventions are being tested in trial NCT02473445?
The interventions under investigation include: Cysteamine Bitartrate (DRUG).
Who is sponsoring clinical trial NCT02473445?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.